Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Aclara Reports Receding Revenue, Narrowed Loss in Q1

NEW YORK, April 30 - Aclara today reported significantly receded revenue, a decrease in operating spending, and a narrowed net loss.

 

Total revenue for the quarter ended March 31 was $590,000 compared with $934,000 in the year-ago period, Aclara said.

 

Operating expenses in the period were $10.8 million, down from $13.4 million Aclara reported for the first quarter 2001. R&D spending grew to $6.2 million in the current quarter from $5.2 million year over year.

 

Net loss narrowed to $9.1 million, or $.25 per share, from $9.8 million, or $.28 per share one year ago.

 

Aclara said it had just under $17 million in cash and cash equivalents as of March 31.

 

For more information, click here.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.